SCHEMBL16627429

SCHEMBL16627429

CC(=O)c1cccnc1Nc1ccc(O)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.58
RAB9A P51151 6/20 0.58
NPC1 O15118 4/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
AHR P35869 1/20 0.58
DHODH Q02127 5/20 0.58
MEN1 O00255 10/20 0.57
KMT2A Q03164 10/20 0.57
ALDH1A1 P00352 3/20 0.57
GAA P10253 2/20 0.57
NPSR1 Q6W5P4 2/20 0.56
HTT P42858 2/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
MAPK1 P28482 2/20 0.53
LMNA P02545 2/20 0.52
KDR P35968 1/20 0.47
TUBB4A P04350 1/20 0.46
TUBB P07437 1/20 0.46
TUBA3C P0DPH7 1/20 0.46
TUBA1B P68363 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL846930 0.87 DHODH (0.76) MAPTRAB9ANPC1SMN1; SMN2AHR
SCHEMBL16616643 0.86 DHODH (0.76) MAPTRAB9ANPC1SMN1; SMN2AHR
SCHEMBL16616388 0.86 RAB9A (0.76) MAPTRAB9ANPC1SMN1; SMN2AHR
SCHEMBL16616459 0.84 MEN1 (0.80) MAPTRAB9ANPC1SMN1; SMN2AHR
SCHEMBL16627432 0.81 RAB9A (0.57) MAPTRAB9ANPC1SMN1; SMN2AHR
SCHEMBL16616153 0.80 MEN1 (0.62) MAPTRAB9ANPC1SMN1; SMN2AHR
SCHEMBL16627422 0.79 ALDH1A1 (0.58) MAPTRAB9ANPC1SMN1; SMN2AHR
SCHEMBL16616664 0.77 LMNA (0.58) MAPTRAB9ANPC1SMN1; SMN2AHR
SCHEMBL12990441 0.76 KMT2A (0.46) MAPTRAB9ANPC1SMN1; SMN2AHR
SCHEMBL16627388 0.76 MAPT (0.45) MAPTRAB9ANPC1SMN1; SMN2AHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9006451-B1 2-anilinonicotinyl based chalcones useful as potential anticancer agents and process for preparation thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-04-14 US disclosed
US-20150099888-A1 2-Anilinonicotinyl Based Chalcones Useful As Potential Anticancer Agents and Process for Preparation Thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099888-A1 2-Anilinonicotinyl Based Chalcones Useful As Potential Anticancer Agents and Process for Preparation Thereof HCCS, WEE2, WEE1 MAPT 2681/4885RAB9A 1415/4885NPC1 1383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.